23/07/2026
Did you know? MiYOSMART iQ spectacle lenses help control myopia progression in children across a wide age range, starting from as young as 4 years of age.
It is HOYA’s first spectacle lens reported to be effective in randomized controlled clinical trials in both younger children aged 4–6 years and older children aged 7–12 years as a monotherapy.¹-³
Ask your Eye Care Professional about MiYOSMART iQ or learn more via the link in comments!
References:
1. Tse DYY, Chun RKM, Hon Y, et. al. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Triple Enhanced Design Spectacle Lenses. The 41st Asia‑Pacific Academy of Ophthalmology Congress, 2026, https://2026.apaophth.org/abstract/?code=205567 (accessed date 28.05.2026).
2. Tse D.Y., Hon Y., Chun R. K., Leung T. W., Leung D. K. Y., To C. H., Lam C SY. Myopia Control Efficacy of Defocus Incorporated Multiple Segments Spectacle lens with Triple Enhanced Design: 12-month randomized controlled trial. Abstract 2523, ARVO 2026 Annual Meeting, Denver, USA. https://eppro02.ativ.me/web/index.php?page=IntHtml&project=ARVO26&id=4486941 (accessed date 28.05.2026)
3. HOYA data on file. HOYA MiYOSMART iQ spectacle lens clinical outcomes. 04/2026.